Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study

Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Sarah Nikiforow(Otsuka (Japan)), Wen‐Kai Weng(Stanford University), Donald E. Tsai(University of Pennsylvania), Nancy Bunin(Children's Hospital of Philadelphia), Eneida R. Nemecek(Oregon Health & Science University), David M. Loeb(Albert Einstein College of Medicine), Koen van Besien(University Hospitals of Cleveland), Kris M. Mahadeo(Duke University), Minoti Hiremath(Yale University), Ran Reshef(Abramson Cancer Center), Sunita D. Nasta(University of Pennsylvania), Yan Sun(Shanghai Jiao Tong University), Rolla Abu‐Arja(Nationwide Children's Hospital), Susan Yue(Atara Biotherapeutics (United States)), Willis H. Navarro(University of California, San Francisco)
Transplantation and Cellular Therapy
January 23, 2020
10.1016/j.bbmt.2019.12.228
Cited by 3

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728